Related Experiment Videos
CR1 deficiency in SLE: acquired or genetic?
Clinical and Experimental Immunology
|November 1, 1985
Summary
Systemic lupus erythematosus (SLE) patients often show acquired defective complement receptor 1 (CR1) activity, which fluctuates with disease activity and anti-DNA binding. This defect appears to be acquired, not genetic.
Area of Science:
- Immunology
- Rheumatology
- Hematology
Background:
- Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by immune system dysregulation.
- Complement receptor 1 (CR1) plays a crucial role in immune complex clearance.
- Deficiencies in CR1 activity have been implicated in various autoimmune conditions.
Purpose of the Study:
- To investigate the prevalence and nature of CR1 activity in patients with SLE.
- To determine if CR1 deficiency in SLE is primarily genetic or acquired.
- To explore the relationship between CR1 activity and disease markers in SLE.
Main Methods:
- Erythrocytes from 30 SLE patients were analyzed for CR1 activity using an immune adherence haemagglutination technique.
- CR1 activity was assessed at multiple time points.
- Serum anti-DNA binding and indicators of complement activation in vivo were measured.
Main Results:
- Defective CR1 activity (CR1D) was observed in 37% of SLE patients initially.
- CR1 activity showed temporal variation and an inverse correlation with serum anti-DNA binding and in vivo complement activation.
- Two patients with initially normal CR1 activity developed CR1D, while one with CR1D normalized during the study.
Conclusions:
- The increased incidence of CR1D in SLE patients is largely an acquired phenomenon, not genetically determined.
- Fluctuations in CR1 activity correlate with SLE disease activity.
- Acquired CR1D may contribute to the pathogenesis of SLE by impairing immune complex clearance.